Obesity Market Segmentation and Analysis

DelveInsight's Obesity Market Insights report provides a detailed analysis of current treatment practices, emerging drugs, market share of individual therapies, and the market size from 2020 to 2034, segmented into seven major markets (7MM) including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Request for Sample report @ Obesity Market

Key Takeaways from the Obesity Market Report

Market Size: The obesity market size in the US was USD 1.2 billion in 2022.
Prevalence: In 2023, the total prevalent population of obesity in the United States was 114 million cases, with expectations of an increase by 2034.
Leading Companies: Companies such as Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and others are developing novel obesity drugs anticipated to enter the market in the coming years.
Emerging Therapies: The pipeline includes promising therapies like Oral semaglutide, Danuglipron, Survodutide, Liraglutide, Cagrilintide, Orforglipron, Setmelanotide, Carbetocin, Pitolisant, and DCCR.
Recent Approvals: In November 2023, the FDA approved Eli Lilly's ZEPBOUND (tirzepatide) injection for obesity treatment. Pfizer announced promising topline data for its oral GLP-1RA candidate, danuglipron, in December 2023.

Obesity Overview

Obesity is a chronic condition characterized by excessive body fat and associated with numerous health risks. It is influenced by genetic and environmental factors, and its development can lead to social and psychological issues such as low self-esteem and depression. Childhood obesity can result in similar health complications as seen in adults, sometimes manifesting earlier.

Genetic predispositions, particularly mutations in genes related to the leptin-melanocortin axis, play a significant role in severe and early-onset obesity. Key indicators include excess adipose tissue and a body mass index (BMI) exceeding 30 kg/m². Symptoms like high blood pressure and stretch marks are common, and obesity increases the risk of developing various diseases.

Obesity Epidemiology Segmentation

According to DelveInsight, the prevalence of diagnosed obesity cases is rising. In 2023, the United States accounted for 61% of adult cases and 66% of childhood cases within the 7MM. The report provides an epidemiological analysis for 2020-2034, segmented into:

Total Prevalent Cases of Obesity
Total Obesity Patients Seeking Help
Total Treated Cases of Obesity

Obesity Treatment Market

Current Treatment Practices

Weight reduction through diet, physical activity, and lifestyle modifications are common treatments for obesity. Some individuals benefit from weight management programs, but others may require alternative therapies such as weight-loss medications, devices, or bariatric surgery. Innovative techniques include:

Hydrogels: Ingestible capsules that absorb water, creating a sense of fullness.
Vagal Nerve Blockade: An implanted device that sends signals to the vagus nerve to indicate fullness.
Gastric Aspirate: A surgical procedure to remove part of the stomach contents post-meal.

FDA-Approved Treatments

CONTRAVE (bupropion-naltrexone): Reduces appetite and cravings.
SAXENDA (liraglutide): Injectable that curbs appetite and slows stomach emptying.
Alli and XENICAL (orlistat): Inhibit pancreatic lipase.
QSYMIA (phentermine-topiramate): Suppresses appetite.
IMCIVREE (setmelanotide): Approved for genetic-based obesity.
WEGOVY (semaglutide): Injectable for weight loss when combined with diet and exercise.

Obesity Pipeline Therapies and Key Companies

Emerging therapies in the pipeline include:

Oral semaglutide (Novo Nordisk)
Danuglipron (PF-06882961) (Pfizer)
Survodutide (BI 456906) (Boehringer Ingelheim)

RYBELSUS (oral semaglutide) has approvals in the US, EU, and Japan for glycemic control in type II diabetes and is being developed for obesity treatment. The drug, currently in Phase III trials, shows promise in managing obesity by mimicking the natural hormone GLP-1.

Danuglipron (Pfizer) is another promising GLP-1R agonist showing significant weight reduction in clinical trials. In June 2023, Pfizer advanced the drug for further evaluation in obesity treatment, with Phase IIb trials indicating positive outcomes.

Late-stage therapies in development include:

Liraglutide (Novo Nordisk)
Cagrilintide (Novo Nordisk)
Orforglipron (Eli Lilly)
Setmelanotide (Rhythm Pharmaceuticals)
Carbetocin (ACADIA Pharmaceuticals)
Pitolisant (Harmony Biosciences)
DCCR (Soleno Therapeutics)

These therapies are expected to transform the obesity market landscape, offering new standards of care and driving medical innovation and economic growth.

Request for Sample report @ Obesity Market

Obesity Market Dynamics

The obesity market is poised for significant changes driven by increased pharmaceutical investments, emerging mobile technologies, and growing awareness. Key players like Novo Nordisk and Eli Lilly are addressing unmet needs, while governmental and nongovernmental organizations work to expand market reach.

Growth Drivers

The introduction of emerging therapies with improved efficacy, better diagnosis rates, and increased patient awareness is expected to drive market growth in the 7MM. The focus on innovative treatments and technologies also offers unprecedented possibilities for understanding and managing obesity.

Challenges

Several factors could impede market growth, including:

Lack of consensus on the best obesity treatment
Disparities in disease staging systems
High costs and reduced patient adherence
Comorbidities requiring additional treatments
Economic burden and impact on quality of life
Market access, reimbursement issues, and specialist shortages
Undiagnosed and unreported cases

Conclusion

The obesity market is evolving with promising new therapies and growing awareness, yet faces challenges that must be addressed. Continued investment in research, innovative treatments, and collaborative efforts among stakeholders are crucial for advancing obesity management and improving patient outcomes. The anticipated launch of emerging therapies will likely reshape the market, setting new standards for care and unlocking opportunities for growth and innovation.

Trending Reports:

DelveInsight:

Become a GamesFree.ca volunteer for a chance to win